3 High-Efficiency and High-Flux Hemodialysis

Hemodialysis remains the major modality of renal replacement therapy in the United States. Since the 1970s the drive for shorter dialysis time with high urea clearance rates has led to the development of high-efficiency hemodialysis. In the 1990s, certain biocompatible features and the desire to remove amyloidogenic 2microglobulin has led to the popularity of high-flux dialysis. During the 1990s, the use of high-efficiency and high-flux membranes has steadily increased and use of conventional membrane has declined [1]. In 1994, a survey by the Centers for Disease Control showed that high-flux dialysis was used in 45% and high-efficiency dialysis in 51% of dialysis centers (Fig. 3-1) [1]. Despite the increasing use of these new hemodialysis modalities the clinical risks and benefits of high-performance therapies are not welldefined. In the literature published over the past 10 years the definitions of high-efficiency and high-flux dialysis have been confusing. Currently, treatment quantity is not only defined by time but also by dialyzer characteristics, ie, blood and dialysate flow rates. In the past, when the efficiency of dialysis and blood flow rates tended to be low, treatment quantity was satisfactorily defined by time. Today, however, treatment time is not a useful expression of treatment quantity because efficiency per unit time is highly variable. Sivasankaran Ambalavanan Gary Rabetoy Alfred K. Cheung

[1]  S. Nishi,et al.  Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. , 1997, Kidney international.

[2]  J T Daugirdas,et al.  Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Hemodialysis (HEMO) Study. , 1997, Kidney international.

[3]  A. Cheung,et al.  The hemodialysis membranes: a historical perspective, current state and future prospect. , 1997, Seminars in nephrology.

[4]  R. Wolfe,et al.  Effect of the dialysis membrane on mortality of chronic hemodialysis patients. , 1996, Kidney international.

[5]  T. Ikizler,et al.  Nutrition in end-stage renal disease. , 1996, Kidney international.

[6]  T A Ikizler,et al.  Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. , 1996, Kidney international.

[7]  J. Chanard Patient survival on PAN/AN 69 membrane hemodialysis. , 1994, Journal of the American Society of Nephrology : JASN.

[8]  J. Hornberger,et al.  A multivariate analysis of mortality and hospital admissions with high-flux dialysis. , 1992, Journal of the American Society of Nephrology : JASN.

[9]  D Luehmann,et al.  Technical requirements for rapid high-efficiency therapies. , 1986, Artificial organs.

[10]  Treatment Modalities for ESRD Patients 33 Chapter III Treatment Modalities for ESRD Patients , 1998 .

[11]  M. Alter,et al.  National surveillance of dialysis associated diseases in the United States--1994. , 1997, ASAIO journal.

[12]  D. Churchill Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: an appraisal of the evidence. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  R. Barth High-flux hemodialysis: overcoming the tyranny of time. , 1993, Contributions to nephrology.

[14]  N. Levin,et al.  Improvement of plasma lipoprotein profiles during high-flux dialysis. , 1993, Journal of the American Society of Nephrology : JASN.

[15]  J. Bosch,et al.  Short hemodialysis. , 1991, American journal of nephrology.